#RGLS

StockTitan

@stocktitan.net

10 months ago

Regulus Therapeutics Reports First Quarter 2025 Financial Results and Recent Updates Regulus Therapeutics (RGLS) has announced its Q1 2025 financial results and significant corporate updates. The company has entered into an acquisition agreement with Novartis for $7.00 per share in cash, plus a potential additional $7.00 per share through a CVR upon achieving regulatory milestones, valuing the deal at up to $1.7 billion. The transaction is expected to close in H2 2025.The company reported positive topline data from the fourth cohort of its Phase 1b MAD study of farabursen (RGLS8429) for ADPKD treatment. The study demonstrated favorable safety profiles and efficacy in halting kidney volume growth. Regulus plans to initiate a Phase 3 pivotal trial in Q3 2025.Q1 2025 financial results showed $65.4 million in cash and investments, with a net loss of $9.6 million ($0.15 per share). R&D expenses were $6.8 million, and G&A expenses were $3.7 million.

#RGLS Regulus Therapeutics Reports First Quarter 2025 Financial Results and Recent Updates

www.stocktitan.net/news/RGLS/regulus-therap...

Thiard News@F4F

@newsen.bsky.social

10 months ago

Halper Sadeh LLC's Shareholder Investigation Includes RGLS, KRON, PPBI, COEP Halper Sadeh LLC has commenced investigations into several companies, including RGLS and KRON, for possible breaches of federal securities laws and fiduciary duties to their shareholders.

Halper Sadeh LLC's Shareholder Investigation Includes RGLS, KRON, PPBI, COEP #United_States #New_York #Halper_Sadeh_LLC #RGLS #KRON

Thiard News@F4F

@newsen.bsky.social

10 months ago

Halper Sadeh LLC Launches Shareholder Investigation on RGLS, KRON, and SWTX for Potential Legal Violations Halper Sadeh LLC is investigating multiple companies, including RGLS and KRON, for potential federal securities laws violations, advising shareholders on their rights.

Halper Sadeh LLC Launches Shareholder Investigation on RGLS, KRON, and SWTX for Potential Legal Violations #United_States #New_York #Halper_Sadeh #RGLS #KRON

InsiderFinance

@insiderfinance.com

10 months ago

🎯 Sweep Options Activity trade ideas! Institutions trading #options urgently with strong consensus on direction.

PM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#SMG, #AUR, #CVX, #ASTS, #RGLS

#OptionFlow #OptionsTrading #Trading

StockQuakes Team

@stockquakes.com

10 months ago

#trading #stock #market #AI #stockmarket #invest #RGLS #stocks #fintech #gainer

Wednesday April 30, 2025

The top UP stock today is stock symbol RGLS, Regulus Therapeutics Inc. with a HUGE StockQuakes level of 20.2.

See StockQuakes.com

StockTitan

@stocktitan.net

10 months ago

Regulus Therapeutics Enters into Agreement to be Acquired by Novartis AG Novartis has agreed to acquire Regulus Therapeutics in a deal worth up to $1.7 billion. The acquisition offers $7.00 per share in upfront cash, representing a 274% premium over Regulus' 60-day volume-weighted average stock price. Shareholders will receive an additional $7.00 per share through a contingent value right (CVR) if certain milestones for their lead product farabursen are met. The deal focuses on advancing treatment for ADPKD (the most common genetic cause of renal failure worldwide) through farabursen, which could become a first-in-class medicine. The transaction, unanimously approved by both companies' boards, is expected to close in the second half of 2025. The merger requires tender of at least a majority of Regulus' shares and regulatory clearance. Evercore serves as financial advisor, with Latham & Watkins as legal counsel to Regulus.

#RGLS Regulus Therapeutics Enters into Agreement to be Acquired by Novartis AG

www.stocktitan.net/news/RGLS/regulus-therap...

Daniel Malik

@danielwmalik.bsky.social

11 months ago

On a fun project- more to come. #RGLS

StockTitan

@stocktitan.net

1 year ago

Regulus Achieves Double Win: FDA Green Light for Phase 3 ADPKD Drug Trial Plus Strong Cash Position Regulus advances ADPKD treatment with positive Phase 1b data and FDA agreement on Phase 3 trial design. $75.8M cash runway extends development into 2026.

#RGLS Regulus Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Recent Updates

www.stocktitan.net/news/RGLS/regulus-therap...

Small Cap Strategist

@smcapstrategist.bsky.social

1 year ago

Small-cap stocks with improving money flow, Wed Mar 12th - #RGLS #SAGE #VIOT #ARMN #DOUG #PFC #OPRX #LENZ #ARTV #IPI #HG #FOA - More: crystalequityresearch.com/SmCpStr/ - #smallcap

StockTitan

@stocktitan.net

1 year ago

Breakthrough in Kidney Disease Treatment: Regulus Drug Shows Promising Results in Clinical Trial Regulus' farabursen demonstrates positive Phase 1b results in ADPKD treatment, reducing kidney volume growth. FDA green-lights Phase 3 trial design with accelerated approval potential.

#RGLS Regulus Therapeutics Announces Positive Clinical and Regulatory Updates from its Autosomal Dominant Polycystic Kidney Disease (ADPKD) Program for Farabursen (RGLS8429)

www.stocktitan.net/news/RGLS/regulus-therap...

StockTitan

@stocktitan.net

1 year ago

#RGLS Regulus Therapeutics Announces Participation at Upcoming Healthcare Investment Conferences

www.stocktitan.net/news/RGLS/regulus-therap...